Preliminary in cell studies show that the (KRI)3 peptide is endowed with higher cytotoxicity against PC-3 prostate carcinoma cell line, in which endogenous levels of both EphA2 and Ship2 are elevated, compared to normal fibroblasts. The gene discussed is EPHA2; the disease is prostate carcinoma.